News from the FDA/CDC

FDA cancels or postpones meetings amid COVID-19 concerns


 

Officials at the Food and Drug Administration’s Center for Drug Evaluation and Research are taking the precautionary step of canceling or postponing advisory committee meetings and limiting staff travel in an effort to help curb the spread of the COVID-19.

FDA icon Wikimedia Commons/FitzColinGerald/ Creative Commons License

“The outbreak of respiratory illness caused by a novel coronavirus, COVID-19, that started in China is spreading to other countries, including the United States,” CDER Director Janet Woodcock, MD, said in a memo to CDER staff. “As a precaution, FDA is canceling foreign official agency travel and limiting domestic travel to mission critical only, effective immediately and through April.”

Additionally, the memo notes that “CDER-organized external meetings, conferences, and workshops will be postponed or canceled from March 10 through April.”

“To mitigate the impact on our work, I encourage you to hold meetings with external stakeholders through teleconference, when possible,” she wrote.

Thus far, only a few CDER events on the FDA’s meeting webpage are listed as being canceled or postponed. Some of the affected meetings include a March 10 public meeting on patient-focused drug development for stimulant-use disorder, a March 11 meeting of the Nonprescription Drug Advisory Committee, and a March 30 public meeting on patient-focused drug development for vitiligo, all of which are postponed until further notice. The Center for Biologics Evaluation and Research also has postponed until further notice its U.S.–Japan Cellular and Gene Therapy Conference, originally scheduled for March 12.

Dr. Woodcock also noted in the memo that in relation to inspections, “we plan to use technology and established agreements with our foreign counterparts to minimize disruptions to the drug supply chain and to applications under review, so that Americans can continue to get their medications.”

Recommended Reading

U.S. reports first death from COVID-19, possible outbreak at long-term care facility
MDedge Hematology and Oncology
Washington State grapples with coronavirus outbreak
MDedge Hematology and Oncology
What medical conferences are being canceled by coronavirus?
MDedge Hematology and Oncology
FDA moves to expand coronavirus testing capacity; CDC clarifies testing criteria
MDedge Hematology and Oncology
CMS issues guidance on containing spread of coronavirus
MDedge Hematology and Oncology
Infection control protects hospital staff from COVID-19, study shows
MDedge Hematology and Oncology
SARS epidemiology provides clues to potential treatment for COVID-19
MDedge Hematology and Oncology
Telehealth seen as a key tool to help fight COVID-19
MDedge Hematology and Oncology
Novel coronavirus may cause environmental contamination through fecal shedding
MDedge Hematology and Oncology
Some infected patients could show COVID-19 symptoms after quarantine
MDedge Hematology and Oncology